Vaccibody to initiate a phase 1/2 trial to evaluate two second-generation SARS CoV-2 virus DNA vaccine candidates to address emerging variants of concern - Vaccibody.com
2814
post-template-default,single,single-post,postid-2814,single-format-standard,bridge-core-2.4.3,qode-page-transition-enabled,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-25.7,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

Vaccibody to initiate a phase 1/2 trial to evaluate two second-generation SARS CoV-2 virus DNA vaccine candidates to address emerging variants of concern

Vaccibody to initiate a phase 1/2 trial to evaluate two second-generation SARS CoV-2 virus DNA vaccine candidates

View press release (PDF)